Weekly injection could be life changing for Parkinson’s patients
Exciting news in Parkinson’s disease (PD) treatment! A new weekly subcutaneous injection is showing promise in clinical trials, potentially replacing daily oral medications for some patients.
Key Highlights:
- Drug Name: ND0612 (developed by NeuroDerm, now part of AbbVie)
- How It Works: A continuous, subcutaneous infusion of levodopa/carbidopa (the gold-standard PD treatment), delivering stable drug levels to avoid motor fluctuations.
- Weekly vs. Daily: Unlike traditional oral levodopa (taken 3-5 times daily), ND0612 is administered via a small pump worn on the body, requiring only weekly refills.
- Benefits:
- Reduces “off” periods (when medication wears off)
- Minimizes dyskinesia (involuntary movements caused by fluctuating drug levels)
- Improves quality of life by simplifying treatment.
Clinical Trial Results:
- Phase 3 (BouNDless trial): Showed significant reduction in “off” time compared to oral levodopa.
- FDA Status: Under priority review, with a decision expected in 2024 or early 2025.
Who Could Benefit?
- PD patients with advanced symptoms and motor fluctuations despite oral meds.
- Those struggling with pill fatigue or absorption issues (common in later-stage PD).
Challenges Ahead:
- Cost & Insurance Coverage: Likely expensive initially.
- Adoption: Requires patient training on pump use.
Future of PD Treatment:
If approved, ND0612 could join other advanced PD therapies like:
- Continuous intestinal gel (Duodopa/Duopa)
- Deep brain stimulation (DBS)
- Monthly/subcutaneous infusions (e.g., ABBV-951)
Reference:
Medications that have been suggested by doctors worldwide are available on below link
https://mygenericpharmacy.com/category/disease/parkinsons-disease